In concordance with our previously published results that genetic ablation of Mertk in myeloma cells inhibits tumor progression in vivo24 we could observe that pharmacologic MERTK blockade by R992 led to reduced tumor burden and bone marrow infiltration after 8 weeks in the U266 myeloma mouse model (Fig. 5a, b) (Supplementary Methods). The gene discussed is MERTK; the disease is plasma cell myeloma.